GT Biopharma GTBP
GT Biopharma: quarterly report for the quarter ended Sep 30, 2020
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001654954-20-012364
- Document
- 10-Q
- Exhibit 10.19
- Settlement agreement
- Exhibit 10.20
- Form of settlement note
- Exhibit 10.21
- Steve weldon letter of resignation
- Exhibit 10.22
- Board service agreement
- Exhibit 10.23
- Board service agreement
- Exhibit 10.24
- Consultant agreement
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Biovie BIVI public float $8M, Dec 31, 2025
- Talphera TLPH public float $8M, Jun 30, 2025
- TherapeuticsMD TXMD public float $9M, Jun 30, 2025
- Oncotelic Therapeutics OTLC public float $9M, Jun 30, 2025
- Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
